Mendus Logo

Mendus

Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.

IMMU | ST

Overview

Corporate Details

ISIN(s):
SE0005003654 (+1 more)
LEI:
529900AFBGFR7ZB50J95
Country:
Sweden
Address:
Västra Trädgårdsgatan 15, 111 53 Stockholm
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Mendus is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer treatment. The company focuses on preventing tumor recurrence by stimulating the patient's immune system to build active immunity against residual cancer cells. Specializing in allogeneic dendritic cell biology, Mendus aims to improve long-term survival outcomes and preserve the quality of life for cancer patients. Its lead product candidate, vididencel, is under development for various malignancies, including ovarian cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 08:00
Regulatory News Service
Mendus meddelar uppdaterad klinisk strategi och operativt fokus
Swedish 138.6 KB
2025-10-02 08:00
Regulatory News Service
Mendus announces updated clinical strategy and operational focus
English 137.5 KB
2025-08-21 08:00
Quarterly Report
Swedish 1.4 MB
2025-08-21 08:00
Quarterly Report
English 1.4 MB
2025-08-20 18:00
Transaction in Own Shares
Mendus AB (publ) has resolved to transfer own shares on Nasdaq Stockholm
English 117.2 KB
2025-08-20 18:00
Transaction in Own Shares
Mendus AB (publ) har beslutat om överlåtelse av egna aktier
Swedish 117.4 KB
2025-06-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Mendus AB (publ)
Swedish 124.2 KB
2025-06-30 08:00
Share Issue/Capital Change
Change in number of shares and votes in Mendus AB (publ)
English 123.6 KB
2025-05-26 17:50
Remuneration Information
Mendus AB (publ) har beslutat om emission av C-aktier och överlåtelse av egna s…
Swedish 117.6 KB
2025-05-26 17:50
Share Issue/Capital Change
Mendus AB (publ) has decided on directed issues of Class C shares and transfer …
English 118.1 KB
2025-05-06 10:10
Post-Annual General Meeting Information
Kommuniké från årsstämma i Mendus AB (publ) den 6 maj 2025
Swedish 128.6 KB
2025-05-06 10:10
Post-Annual General Meeting Information
Report from the Annual General Meeting of Mendus AB (publ) on 6 May 2025
English 128.9 KB
2025-05-06 08:00
Earnings Release
Swedish 1.4 MB
2025-05-06 08:00
Quarterly Report
English 1.4 MB
2025-02-13 08:00
Earnings Release
Swedish 1.5 MB

Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Mendus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-11-05 Ann-Charlotte Ferm Other Buy 4,327 16,637.32 SEK
2021-11-05 Ann-Charlotte Ferm Other Buy 1,347 5,226.36 SEK
2021-11-04 Ann-Charlotte Ferm Other Buy 10,000 36,770.72 SEK
2021-11-04 Ann-Charlotte Ferm Other Buy 20,000 70,400.00 SEK
2021-11-04 Ann-Charlotte Ferm Other Buy 5,000 17,650.00 SEK
2021-11-04 Ann-Charlotte Ferm Other Buy 5,000 17,728.82 SEK
2021-11-04 Ann-Charlotte Ferm Other Buy 10,000 35,849.00 SEK
2021-06-17 Jeroen Rovers Other Buy 534,000 2,445,720.00 SEK
2021-05-11 Helen Tuvesson Andersson Other Buy 2,000 10,800.00 SEK
2021-05-07 Helen Tuvesson Andersson Other Buy 14,000 75,600.00 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.